Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

Vertex Pharmaceuticals (NASDAQ ... Image source: Getty Images. First, let's consider the Vertex story so far. The company has built a CF empire, offering several treatments known as CFTR modulators.

Cannabix Technologies Inc. (the "Company" or "Cannabix") developer of marijuana and alcohol breath testing devices is pleased to report that it has made significant updates to its Cannabix Marijuana ...

If approved, the drug, developed by Vertex Pharmaceuticals in Boston ... will look deeper into the Sun’s atmosphere, capturing 3D images that will help to clear up questions about how that ...

Realistic Expectations for 10 Disruptive Technologies in 2025 The new year is here, and 2025 has the potential to be one of the most exciting moments in a long time. Momentum continues to build around ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.